8-K: BioMarin Reports Record 2023 Results and Provides Optimistic 2024 Guidance

BioMarin announced record financial results for 2023, driven by strong sales of VOXZOGO, and provided a positive financial outlook for 2024.

Summary

• BioMarin reported a 15% year-over-year increase in total revenue for 2023, reaching $2.42 billion.
• VOXZOGO net revenues were $470 million for the year, a 178% increase compared to 2022.
• The company's GAAP diluted earnings per share for 2023 was $0.87, a 16% increase year-over-year.
• Non-GAAP diluted earnings per share for 2023 was $2.08, a 36% increase year-over-year.
• For the fourth quarter of 2023, total revenues were $646.2 million, a 20% increase compared to the same period in 2022.
• The company anticipates double-digit total revenue growth for 2024, with a projected revenue range of $2.7 billion to $2.8 billion.
• BioMarin expects significant non-GAAP operating margin expansion and non-GAAP earnings per share to grow faster than revenues in 2024.
• The company is focusing on maximizing the VOXZOGO opportunity, expanding global access for ROCTAVIAN, prioritizing R&D, and driving operational excellence.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to record financial results, strong growth in key products, and optimistic future guidance. The company's strategic focus and successful product launches contribute to a high level of confidence.

Positives

• Strong revenue growth driven by VOXZOGO and established enzyme products.
• Significant increase in VOXZOGO sales, particularly after FDA approval for younger children.
• Substantial growth in both GAAP and non-GAAP earnings per share.
• Positive financial outlook for 2024 with expected double-digit revenue growth and margin expansion.
• Increase in the number of children being treated with VOXZOGO.
• Approval of ROCTAVIAN reimbursement in Italy.
• Strategic focus on value creation through key priorities.

Negatives

• KUVAN product revenues decreased due to generic competition.
• Increased R&D and SG&A expenses impacted net income.
• The company experienced an asset impairment charge and corporate governance transition costs.
• There was a decrease in income tax benefits and an investment loss in Q4 2023.

Risks

• The company faces risks related to the commercialization of its products.
• Macroeconomic and external factors could impact operations.
• There are risks associated with clinical trials and regulatory approvals.
• The company is exposed to the risk of generic competition, particularly for KUVAN.
• The company's ability to manufacture its products successfully is a risk factor.
• There are risks associated with the timing of orders for commercial products.

Future Outlook

BioMarin anticipates double-digit total revenue growth in 2024, with significant non-GAAP operating margin expansion and non-GAAP earnings per share growing faster than revenues. The company plans to maximize the VOXZOGO opportunity, expand global access for ROCTAVIAN, prioritize R&D, and drive operational excellence.

Management Comments

• Alexander Hardy, President and Chief Executive Officer of BioMarin, stated that strong financial results in 2023 were driven by global demand for VOXZOGO and contributions from established enzyme products.
• He also noted that VOXZOGO revenues were positively impacted by an increase in prescriptions for children in the United States under the age of 5, following the FDA approval.

Industry Context

BioMarin's strong performance, particularly with VOXZOGO, highlights the growing market for rare disease treatments. The company's focus on genetic therapies aligns with broader industry trends in personalized medicine and targeted treatments. The expansion of VOXZOGO's label to include younger children is a significant development in the treatment of achondroplasia.

Comparison to Industry Standards

• BioMarin's 15% revenue growth in 2023 is strong compared to the average growth rate of the biotechnology sector, which has seen a more modest growth in recent years.
• The 178% year-over-year growth in VOXZOGO revenue is exceptional, indicating a successful launch and strong market demand, which is significantly higher than the average growth of similar rare disease drugs.
• Companies like Vertex Pharmaceuticals, which also focuses on rare diseases, have seen strong growth, but BioMarin's VOXZOGO growth is particularly notable.
• The company's non-GAAP EPS growth of 36% is also impressive, exceeding the average growth of many established biotech companies.
• Compared to companies like Sarepta Therapeutics, which also focuses on genetic therapies, BioMarin's revenue growth and profitability metrics are competitive and show strong market traction.

Stakeholder Impact

• Shareholders will benefit from the strong financial performance and positive outlook.
• Employees may see increased job security and potential for growth.
• Patients will have increased access to innovative therapies.
• Customers will benefit from the company's focus on product expansion.
• Suppliers may see increased demand for their products and services.
• Creditors will have increased confidence in the company's ability to meet its obligations.

Next Steps

• BioMarin will continue to focus on maximizing the VOXZOGO opportunity.
• The company will continue to build out global access channels for ROCTAVIAN.
• BioMarin will prioritize the most potentially impactful R&D candidates.
• The company will drive operational excellence and cost optimization.
• BioMarin will provide updates on its strategic portfolio review at its Investor Day later in 2024.
• The company will engage global health authorities regarding development programs in idiopathic short stature and multiple genetic short stature pathway conditions.

Key Dates

Keywords

BioMarin, VOXZOGO, ROCTAVIAN, Financial Results, Earnings, Revenue, Biotechnology, Rare Diseases, Achondroplasia, Hemophilia A, Pharmaceuticals